Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Practice Guidelines for the Treatment of Coccidioidomycosis

Open access
Galgiani, J. N., Ampel, N. M., Catanzaro, A., Johnson, R. H., Stevens, D. A., Williams, P. L.·2000·Clinical Infectious Diseases

Abstract

Management of patients diagnosed with coccidioidomycosis involves defining the extent of infection and assessing host factors that predispose to disease severity. Patients with relatively localized acute pulmonary infections and no risk factors for complications often require only periodic reassessment to demonstrate resolution of their self-limited process. On the other hand, patients with extensive spread of infection or at high risk of complications because of immunosuppression or other preexisting factors require a variety of treatment strategies that may include antifungal therapy, surgical debridement, or both. Amphotericin B is often selected for treatment of patients with respiratory failure due to Coccidioides immitis or rapidly progressive coccidioidal infections. With other more chronic manifestations of coccidioidomycosis, treatment with fluconazole, itraconazole, or ketoconazole is common. Duration of therapy often ranges from many months to years, and, for some patients, chronic suppressive therapy is needed to prevent relapses. Coccidioidomycosis results from inhaling the spores (arthroconidia) of Coccidioides immitis. Most infections in the United States occur within the major regions of endemicity in southern Arizona, central California, southern New Mexico, and west Texas. Travelers who visit these regions of endemicity and immunosuppressed patients in whom latent infections reactivate can require medical management in other parts of the country [1]. Of the estimated 100,000 infections per year, one-half to two-thirds are subclinical, and most patients with these infections are protected from second primary infections. The most common clinical presentation in diagnosed cases of coccidioidomycosis is acute or subacute pneumonic illness. Approximately 5%–10% of infections result in residual pulmonary sequelae, usually nodules or peripheral thin-walled cavities. An even smaller proportion of all infections, perhaps 0.5%–1.0%, result in illnesses related to chronic pulmonary or extrapulmonary infection. Although virtually any site in the body may be involved, extrapulmonary dissemination most frequently involves the skin, the skeletal system, and the meninges [2–4]. Objective. The objective of this practice guideline is to provide recommendations about which patients with coccidioidomycosis are likely to benefit from treatment and for which therapies are most appropriate for various forms of infection. Treatment options. Coccidioidomycosis encompasses a spectrum of illnesses ranging from primary uncomplicated respiratory tract infection that resolves spontaneously to progressive pulmonary or disseminated infection. For this reason, management strategies vary widely from patient to patient. Although disease will resolve in most patients who present with early infections without specific antifungal therapy, management should routinely include repeated patient encounters for 1–2 years, either to document resolution or to identify, as early as possible, evidence of pulmonary or extrapulmonary complications. Patients who develop progressive pulmonary disease or disseminated disease warrant antifungal therapy, which is typically prolonged—potentially lifelong—especially for patients with overt immunocompromised conditions. Exact management guidelines for these clinical forms will vary according to disease type and, to an extent, must be individualized. For example, the role of surgical debridement, which in some cases is a critical component of therapy, is not addressed in this practice guideline. However, all patients with progressive or disseminated disease will require some combination of periodic physical examinations, laboratory studies, and radiological studies to guide management decisions. Specific antifungals (and their usual dosages) for treatment of coccidioidomycosis include amphotericin B (0.5–0.7 mg/kg/d iv), ketoconazole (400 mg/d po), fluconazole (400–800 mg/d po or iv), and itraconazole (200 mg b.i.d. po). If itraconazole is used, measurement of serum concentrations of itraconazole after 2 weeks may determine if absorption is satisfactory. In general, the more rapidly progressive a coccidioidal infection is, the more likely amphotericin B will be selected by most authorities for initial therapy. Conversely, subacute or chronic presentations are more likely to be treated initially with an azole. Outcomes. Desired outcomes of treatment are resolution of signs and symptoms of infection, reduction of serum concentrations of antibodies to C. immitis, and return of function of involved organs. It would also be desirable to prevent relapse of illness upon discontinuation of therapy, although current therapy is often unable to achieve this goal. Evidence. Before the availability of antifungal therapy, the natural history of initial pulmonary infections revealed that these infections resolved in at least 95% of patients. Randomized, prospective clinical trials of antifungals have not been co

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1086/313747

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 275

Metadata

Authors
Galgiani, J. N., Ampel, N. M., Catanzaro, A., Johnson, R. H., Stevens, D. A., & Williams, P. L.
Venue
Clinical Infectious Diseases
Published
2000-04-01
Volume
30
Issue
4
Pages
658-661
ISSN
  • 1058-4838 (ISSN-L)
  • 1537-6591
OpenAlex
W2164174337
Cited by
275
References
21
FWCI
13.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.